It has been demonstrated that the efficacy of lapatinib to inhibit HER2-amplified breast cancer cells is severely reduced in a rigid microenvironment in a phenomenon that depends directly on the YAP and TAZ Hippo pathway transcriptional coactivators [52]. Here, ERBB2 is linked to breast cancer.